Citadel Advisors
PRME icon

Citadel Advisors’s Prime Medicine PRME Stock Holding History

Citadel Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$561K Sell
161,300
-27,800
-15% -$106K ﹤0.01% 9027
2025
Q4 		$656K Buy
189,100
+58,300
+45% +$259K ﹤0.01% 8357
2025
Q3 		$725K Buy
130,800
+55,200
+73% +$224K ﹤0.01% 8258
2025
Q2 		$187K Buy
75,600
+73,200
+3,050% +$113K ﹤0.01% 10736
2025
Q1 		$4.78K Sell
2,400
-40,200
-94% -$103K ﹤0.01% 13865
2024
Q4 		$124K Sell
42,600
-7,500
-15% -$26.3K ﹤0.01% 11136
2024
Q3 		$194K Sell
50,100
-23,900
-32% -$111K ﹤0.01% 10197
2024
Q2 		$380K Buy
74,000
+16,300
+28% +$98.8K ﹤0.01% 8624
2024
Q1 		$404K Buy
57,700
+15,700
+37% +$119K ﹤0.01% 8845
2023
Q4 		$372K Buy
42,000
+31,800
+312% +$245K ﹤0.01% 8711
2023
Q3 		$97.3K Buy
+10,200
New +$132K ﹤0.01% 10938

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Citadel Advisors's PRME Position: Q1 2026 in Review

Citadel Advisors increased its Prime Medicine (PRME) stake by 198% in Q1 2026, buying an estimated $851K and bringing the position to 336,358 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #7302.

Citadel Advisors first reported a position in PRME in Q3 2023 and has held it in 8 quarters since. The position peaked at $4.99M in Q3 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Citadel Advisors held 336,358 shares of Prime Medicine worth $1.17M as of Q1 2026.
  • Citadel Advisors bought 223,488 Prime Medicine shares in Q1 2026, an estimated $851K.
  • Prime Medicine made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7302 holding.
  • Citadel Advisors first reported a position in Prime Medicine in Q3 2023 and has held it in 8 quarters since.
  • Citadel Advisors's Prime Medicine position peaked at $4.99M in Q3 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.